Important role of mast cells in multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 5, Issue , 2016, Pages 77-80

  Conti, P ^a   Kempuraj, D ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Immunity; Inflammation; Mast cells; Multiple sclerosis

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL COMMUNICATION; CELL FUNCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATION; DISEASE ASSOCIATION; IMMUNOREGULATION; INNATE IMMUNITY; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; BRAIN; HUMAN; IMMUNOLOGY; INFLAMMATION; MYELIN SHEATH;

ANIMALS; BRAIN; HUMANS; INFLAMMATION; MAST CELLS; MULTIPLE SCLEROSIS; MYELIN SHEATH;

EID: 84960482169     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.11.005     Document Type: Review

References (57)

1. Aydin, O.F., Ichiyama, T., Anlar, B., 2010. Serum and cerebrospinal fluid cytokine concentrations in subacute sclerosing panencephalitis. Brain Dev. 32 (6), 463-466.
2. Bennett, J.L., Stüve, O., 2009. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol. 32 (3), 121-132, May-Jun.
3. + myelin peptide-specific T cells: importance of IFN-inducible protein 10. J. Immunol. 160 (1), 444-448.
4. Barbu, E.A., Zhang, J., Siraganian, R.P., 2010. The limited contribution of Fyn and Gab2 to the high affinity IgE receptor signaling in mast cells. J. Biol. Chem. 285 (21), 15761-15768.
5. Batoulis, H., Addicks, K., Kuerten, S., 2010. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Ann. Anat. 192 (4), 179-193.
6. Correale, J., 2014. The role of microglial activation in disease progression. Mult. Scler. 20 (10), 1288-1295.
7. Conti, P., Youinou, P., Theoharides, T.C., 2007. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun. Rev. 6 (3), 131-137.
8. Coyle, P.K., Procyk-Dougherty, Z., 1984. Multiple sclerosis immune complexes: an analysis of component antigens and antibodies. Ann. Neurol. 16 (6), 660-667.
9. Carrieri, P.B., Provitera, V., De Rosa, T., et al., 1998. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol. Immunotoxicol. 20 (3), 373-382.
10. Conti, P., Pang, X., Boucher, W., et al., 1997. Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 89 (11), 4120-4127.
11. Correale, J., Farez, M.F., 2011. The impact of environmental infections (parasites) on MS activity. Mult. Scler. 17 (10), 1162-1169.
12. Dimisianos, N., Rodi, M., Kalavrizioti, D., et al., 2014. Cytokines as biomarkers of treatment response to IFN β in relapsing-remitting multiple sclerosis. Mult. Scler. Int. 2014, 436764.
13. Fukaura, H., Kikuchi, S., 2003. IL-18 in multiple sclerosis. Nihon Rinsho 61 (8), 1416-1421.
14. Fouillet, A., Mawson, J., Suliman, O., Sharrack, B., Romero, I.A., Woodroofe, M.N., 2012. CCL2 binding is CCR2 independent in primary adult human astrocytes. Brain Res. 1437, 115-126.
15. Frenzel, L., Hermine, O., 2013. Mast cells and inflammation. Jt. Bone Spine 80 (2), 141-145.
16. Gironi, M., Borgiani, B., Cursano, C., et al., 2014. The peripheral network between oxidative stress and inflammation in multiple sclerosis. Eur. J. Inflamm. 12, 351-363.
17. Hafler, D.A., Weiner, H.L., 1987. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol. Rev. 100, 307-332.
18. Huang, Y.M., Xiao, B.G., Ozenci, V., et al., 1999. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J. Neuroimmunol. 99 (1), 82-90.
19. Jack, C., Ruffini, F., Bar-Or, A., Antel, J.P., 2005. Microglia and multiple sclerosis. J. Neurosci. Res. 81 (3), 363-373.
20. Kritas, S.K., Saggini, A., Varvara, G., et al., 2013. Mast cell involvement in rheumatoid arthritis. J. Biol. Regul. Homeost. Agents 27 (3), 655-660.
21. Korn, T., Reddy, J., Gao, W., et al., 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13 (4), 423-431.
22. Kraus, J., Kuehne, B.S., Tofighi, J., et al., 2002. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol. Scand. 105 (4), 300-308.
23. Kritas, S.K., Saggini, A., Cerulli, G., et al., 2014. Neuropeptide NGF mediates neuroimmune response and inflammation through mast cell activation. J. Biol. Regul. Homeost. Agents 28 (2), 177-181.
24. Karamitopoulou, E., Shoni, M., Theoharides, T.C., 2014. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. Int. J. Immunopathol. Pharmacol. 27 (2), 213-220.
25. Kritas, S.K., Saggini, A., Cerulli, G., et al., 2014. Asthma and mast cell biology. Eur. J. Inflamm. 12, 261-265.
26. Karagkouni, A., Alevizos, M., Theoharides, T.C., 2013. Effect of stress on brain inflammation and multiple sclerosis. Autoimmun. Rev. 12 (10), 947-953.
27. Kritas, S.K., Caraffa, A., Antinolfi, P., et al., 2014. IgE generation and mast cell activation. Eur. J. Inflamm. 12, 21-25.
28. Kritas, S.K., Saggini, A., Cerulli, G., et al., 2014. Corticotropin-releasing hormone, microglia and mental disorders. Int. J. Immunopathol. Pharmacol. 27 (2), 163-167.
29. Kritas, S.K., Saggini, A., Varvara, G., et al., 2013. Luteolin inhibits mast cell-mediated allergic inflammation. J. Biol. Regul. Homeost. Agents 27 (4), 955-959.
30. Kim, D.Y., Hong, G.U., Ro, J.Y., 2011. Signal pathways in astrocytes activated by crosstalk between of astrocytes and mast cells through CD40-CD40L. J. Neuroinflamm. 8, 25.
31. Lassmann, H., 1998. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 4 (3), 93-98.
32. Link, H., 1998. The cytokine storm in multiple sclerosis. Mult. Scler. 4 (1), 12-15, Feb.
33. Lock, C., Hermans, G., Pedotti, R., et al., 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508.
34. Moransard, M., Sawitzky, M., Fontana, A., et al., 2010. Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis. Glia 58 (5), 559-571.
35. Minami, M., 2001. Cytokines and chemokines: mediators for intercellular communication in the brain. Yakugaku Zasshi 121 (12), 875-885.
36. Mouzaki, A., Deraos, S., Chatzantoni, K., 2005. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides. Curr. Med. Chem. 12 (13), 1537-1550.
37. Milovanovic, M., Volarevic, V., Radosavljevic, G., et al., 2012. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52 (1-2), 89-99.
38. Mayo, L., Quintana, F.J., Weiner, H.L., 2012. The innate immune system in demyelinating disease. Immunol. Rev. 248 (1), 170-187.
39. Medic, N., Vita, F., Abbate, R., et al., 2008. Mast cell activation by myelin through scavenger receptor. J. Neuroimmunol. 200 (1-2), 27-40.
40. Nelissen, S., Vangansewinkel, T., Geurts, N., et al., 2014. Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. Neurobiol. Dis. 62, 260-272.
41. Owens, T., 2014. The complex immunology of multiple sclerosis. Mult. Scler. 20 (8), 1023-1024.
42. Podojil, J.R., Liu, L.N., Marshall, S.A., et al., 2013. B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J. Autoimmun. 44, 71-81.
43. Prat, A., Biernacki, K., Wosik, K., Antel, J.P., 2001. Glial cell influence on the human blood-brain barrier. Glia 36 (2), 145-155.
44. Runia, T.F., van Pelt-Gravesteijn, E.D., Hintzen, R.Q., 2012. Recent gains in clinical multiple sclerosis research. CNS Neurol. Disord. Drug. Targets 11 (5), 497-505.
45. Romagnoli, P.A., Premenko-Lanier, M.F., Loria, G.D., et al., 2013. CD8 T cell memory recall is enhanced by novel direct interactions with CD4 T cells enabled by MHC class II transferred from APCs. PLoS One 8 (2), e56999.
46. Rozniecki, J.J., Hauser, S.L., Stein, M., Lincoln, R., Theoharides, T.C., 1995. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann. Neurol. 37 (1), 63-66.
47. Ransohoff, R.M., Brown, M.A., 2012. Innate immunity in the central nervous system. J. Clin. Investig. 122 (4), 1164-1171.
48. Sharief, M.K., 1998. Cytokines in multiple sclerosis: pro-inflammation or proremyelination? Mult. Scler. 4 (3), 169-173.
49. Samayawardhena, L.A., Pallen, C.J., 2010. PTPalpha activates Lyn and Fyn and suppresses Hck to negatively regulate FcepsilonRI-dependent mast cell activation and allergic responses. J. Immunol. 185 (10), 5993-6002.
50. Secor, V.H., Secor, W.E., Gutekunst, C.A., Brown, M.A., 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191 (5), 813-822.
51. Talbot, P.J., Paquette, J.S., Ciurli, C., et al., 1996. Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann. Neurol. 39 (2), 233-240.
52. Theoharides, T.C., Kempuraj, D., Iliopoulou, B.P., 2007. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv. Exp. Med. Biol. 601, 423-430.
53. Totaro, R., Lugaresi, A., Bellantonio, P., et al., 2014. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int. J. Immunopathol. Pharmacol. 27 (2), 147-154.
54. Trebst, C., Staugaitis, S.M., Kivisäkk, P., et al., 2003. CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am. J. Pathol. 162 (2), 427-438.
55. Theoharides, T.C., Konstantinidou, A.D., 2007. Corticotropin-releasing hormone and the blood-brain-barrier. Front. Biosci. 12, 1615-1628.
56. Van den Broek, H.H., Damoiseaux, J.G., De Baets, M.H., et al., 2005. The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review. Mult. Scler. 11 (3), 349-359.
57. + T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol. Rev. 238 (1), 247-262.